Stimulating IL-2C treatment potentiated anti-tumor immunity without causing significant side effects; however, given that the immune-enhancing effects of IL-2C were not sufficiently strong to suppress RCC growth, its use in combination with other therapy should be considered.
7-AAD: 7-aminoactinomycin D; APC: Allophycocyanin; FITC: Fluorescein isothiocyanate; Foxp3: Forkhead homeobox protein 3; IFN: Interferon; IL: Interleukin; IL-2C: Complex of interleukin (IL)-2 and stimulating anti-IL-2 antibody; NK cell: Natural killer cell; PBS: Phosphate-buffered saline; PE: Phycoerythrin; RCC: Renal cell carcinoma; RENCA: Murine renal cell carcinoma.
This work was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111355), and by a grant (0320140430, 2014-1033) from the SNUH Research Fund. We thank Charles D Surh for providing anti-IL-2 antibody.
BMC Urol. 2016;16(2) © 2016 BioMed Central, Ltd.